Spaces:
Sleeping
Sleeping
| """ | |
| Data Constants - SUD Categories, Drug/Project Templates, Synthetic Data Settings | |
| All data generation and template related constants | |
| """ | |
| # ======================================== | |
| # SUD CATEGORIES (Used in generate_synthetic_data) | |
| # ======================================== | |
| SUD_CATEGORY_DESCRIPTIONS = { | |
| "Opioid-Related Disorders": "Addiction to opioids including prescription painkillers, heroin, and fentanyl", | |
| "Alcohol Use Disorder": "Problematic pattern of alcohol use leading to clinically significant impairment", | |
| "Stimulant Use Disorder": "Addiction to cocaine, methamphetamine, or prescription stimulants", | |
| "Cannabis Use Disorder": "Problematic cannabis use with withdrawal and tolerance symptoms", | |
| "Sedative/Hypnotic Disorder": "Dependence on benzodiazepines or other sedative medications", | |
| "Nicotine Use Disorder": "Tobacco/nicotine dependence and addiction", | |
| } | |
| SUD_CATEGORY_COLORS = { | |
| "Opioid-Related Disorders": "#1E6B52", | |
| "Alcohol Use Disorder": "#008C95", | |
| "Stimulant Use Disorder": "#5A9B7F", | |
| "Cannabis Use Disorder": "#16533E", | |
| "Sedative/Hypnotic Disorder": "#4A8B7A", | |
| "Nicotine Use Disorder": "#2C7A64", | |
| } | |
| DISEASE_SEARCH_CONFIG = { | |
| "Opioid-Related Disorders": { | |
| "search_terms": ["Opioid-Related Disorders"], | |
| }, | |
| "Alcohol Use Disorder": { | |
| "search_terms": ["Alcoholism"], | |
| }, | |
| "Stimulant Use Disorder": { | |
| "search_terms": ["Stimulant Use Disorder"], | |
| }, | |
| "Cannabis Use Disorder": { | |
| "search_terms": ["Cannabis Use Disorder"], | |
| }, | |
| "Nicotine Use Disorder": { | |
| "search_terms": ["Tobacco Use Disorder"], | |
| }, | |
| "Sedative/Hypnotic Disorder": { | |
| "search_terms": ["Sedative/Hypnotic Disorder"], | |
| }, | |
| } | |
| # ======================================== | |
| # DRUG TEMPLATES (Used in generate_synthetic_data) | |
| # ======================================== | |
| DRUG_TEMPLATES = { | |
| "Opioid-Related Disorders": [ | |
| ("Naltrexone", "Alcohol/opioid dependence", "μ-opioid receptor antagonist", "S5"), | |
| ("Buprenorphine", "Opioid dependence", "Partial μ-opioid agonist", "S6"), | |
| ("Lofexidine", "Hypertension", "α2-adrenergic agonist", "S4"), | |
| ("Gabapentin", "Epilepsy, neuropathic pain", "GABA analog", "S4"), | |
| ("Topiramate", "Epilepsy, migraine", "GABA modulator", "S3"), | |
| ("Ondansetron", "Nausea/vomiting", "5-HT3 antagonist", "S2"), | |
| ("Clonidine", "Hypertension", "α2-adrenergic agonist", "S3"), | |
| ("Memantine", "Alzheimer's disease", "NMDA antagonist", "S2"), | |
| ("Prazosin", "Hypertension", "α1-adrenergic antagonist", "S1"), | |
| ("Mirtazapine", "Depression", "α2-adrenergic antagonist", "S2"), | |
| ], | |
| "Alcohol Use Disorder": [ | |
| ("Acamprosate", "Alcohol dependence", "NMDA antagonist", "S5"), | |
| ("Naltrexone", "Opioid dependence", "μ-opioid antagonist", "S5"), | |
| ("Baclofen", "Muscle spasticity", "GABA-B agonist", "S4"), | |
| ("Topiramate", "Epilepsy", "GABA modulator", "S4"), | |
| ("Varenicline", "Smoking cessation", "Nicotinic receptor agonist", "S3"), | |
| ("Ondansetron", "Nausea/vomiting", "5-HT3 antagonist", "S3"), | |
| ("Gabapentin", "Epilepsy", "GABA analog", "S2"), | |
| ("Zonisamide", "Epilepsy", "Carbonic anhydrase inhibitor", "S1"), | |
| ], | |
| "Stimulant Use Disorder": [ | |
| ("Modafinil", "Narcolepsy", "Dopamine reuptake inhibitor", "S4"), | |
| ("Bupropion", "Depression", "NDRI", "S4"), | |
| ("Topiramate", "Epilepsy", "GABA modulator", "S3"), | |
| ("N-acetylcysteine", "Acetaminophen overdose", "Antioxidant", "S3"), | |
| ("Mirtazapine", "Depression", "α2-antagonist", "S2"), | |
| ("Atomoxetine", "ADHD", "NRI", "S1"), | |
| ], | |
| "Cannabis Use Disorder": [ | |
| ("N-acetylcysteine", "Acetaminophen overdose", "Antioxidant", "S3"), | |
| ("Gabapentin", "Epilepsy", "GABA analog", "S3"), | |
| ("Zolpidem", "Insomnia", "GABA-A modulator", "S2"), | |
| ("Dronabinol", "Nausea/vomiting", "CB1 agonist", "S2"), | |
| ("Buspirone", "Anxiety", "5-HT1A agonist", "S1"), | |
| ], | |
| "Sedative/Hypnotic Disorder": [ | |
| ("Flumazenil", "Benzodiazepine overdose", "GABA-A antagonist", "S3"), | |
| ("Gabapentin", "Epilepsy", "GABA analog", "S3"), | |
| ("Pregabalin", "Neuropathic pain", "GABA analog", "S2"), | |
| ], | |
| "Nicotine Use Disorder": [ | |
| ("Varenicline", "Smoking cessation", "Nicotinic receptor agonist", "S6"), | |
| ("Cytisine", "Smoking cessation (EU)", "Nicotinic receptor agonist", "S5"), | |
| ("Bupropion", "Depression", "NDRI", "S5"), | |
| ("Naltrexone", "Opioid dependence", "μ-opioid antagonist", "S4"), | |
| ], | |
| } | |
| # ======================================== | |
| # PROJECT TEMPLATES (Used in generate_synthetic_data) | |
| # ======================================== | |
| PROJECT_TEMPLATES = [ | |
| { | |
| "name": "NIDA Clinical Trial NCT02892123", | |
| "type": "Clinical Trial", | |
| "size_range": (150, 500), | |
| "impact_range": (0.10, 0.20), | |
| "summary": "Randomized controlled trial showing significant reduction in relapse rates" | |
| }, | |
| { | |
| "name": "Meta-Analysis Lee et al. 2024", | |
| "type": "Meta-Analysis", | |
| "size_range": (800, 3000), | |
| "impact_range": (0.08, 0.15), | |
| "summary": "Pooled analysis of multiple RCTs demonstrating efficacy across populations" | |
| }, | |
| { | |
| "name": "RWE Claims Database Analysis", | |
| "type": "Real-World Evidence", | |
| "size_range": (2000, 10000), | |
| "impact_range": (0.05, 0.12), | |
| "summary": "Insurance claims data showing real-world treatment adherence and outcomes" | |
| }, | |
| { | |
| "name": "Biomarker Validation Study", | |
| "type": "Biomarker Study", | |
| "size_range": (50, 200), | |
| "impact_range": (0.06, 0.10), | |
| "summary": "Identification of predictive biomarkers for treatment response" | |
| }, | |
| { | |
| "name": "Phase II Safety Trial", | |
| "type": "Clinical Trial", | |
| "size_range": (100, 300), | |
| "impact_range": (0.07, 0.13), | |
| "summary": "Safety and tolerability data in target SUD population" | |
| }, | |
| { | |
| "name": "Safety Concern Report FDA-2024", | |
| "type": "Safety Analysis", | |
| "size_range": (80, 250), | |
| "impact_range": (-0.15, -0.08), | |
| "summary": "Adverse event reports indicating potential safety concerns in target population" | |
| }, | |
| { | |
| "name": "Negative RCT Results Study", | |
| "type": "Clinical Trial", | |
| "size_range": (120, 400), | |
| "impact_range": (-0.12, -0.06), | |
| "summary": "Randomized trial showing no significant efficacy compared to placebo" | |
| }, | |
| ] | |
| # ======================================== | |
| # METRICS & ANALYTICS (Used in analytics functions) | |
| # ======================================== | |
| AVERAGE_TIME_TO_IND = 12.7 # months | |
| CURRENT_IND_READY_COUNT = 2 | |
| TIME_BINS_LABELS = ['6-9', '9-12', '12-15', '15-18', '18-21', '21-24', '24+'] | |
| TIME_BINS_COUNTS = [10, 16, 25, 31, 39, 42, 49] | |
| QUARTERLY_DELIVERIES = [ | |
| {'quarter': 'Sep 2025', 'year': 2025, 'count': 0, 'cumulative': 0}, | |
| {'quarter': 'Jan 2026', 'year': 2026, 'count': 0.5, 'cumulative': 0.5}, | |
| {'quarter': 'Apr 2026', 'year': 2026, 'count': 0.3, 'cumulative': 0.8}, | |
| {'quarter': 'Jun 2026', 'year': 2026, 'count': 1.2, 'cumulative': 2.0}, | |
| {'quarter': 'Sep 2026', 'year': 2026, 'count': 0, 'cumulative': 2.0}, | |
| ] |